Answers are grounded in this paper and cite their sources.
Accumulating evidence suggests that B lymphocyte dysfunction plays a critical yet underappreciated role in tumor immune evasion. Beyond regulatory B cell (Breg)-mediated immunosuppression, defects in tumor-infiltrating B cell antigen presentation, immunosuppressive antibody isotypes, and aberrant B cell spatial organization can undermine sustained anti-tumor immunity, ultimately compromising both clinical outcomes and the efficacy of immunotherapies. These findings highlight the need to target non-Breg-mediated immunosuppression beyond Bregs alone. To be effective, therapeutic strategies must accomplish two objectives in the tumor immune microenvironment: convert the tumor microenvironment from immunosuppressive to immunostimulatory and transform weak anti-tumor responses into robust ones. Achieving this will require novel approaches that combine spatiotemporal transcriptomic analysis with precision-targeted interventions to dismantle B-cell-driven immunosuppressive mechanisms and fully realize the therapeutic potential of cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: